HRP20190406T1 - Inhibitori gsk3 i postupci njihove uporabe - Google Patents

Inhibitori gsk3 i postupci njihove uporabe Download PDF

Info

Publication number
HRP20190406T1
HRP20190406T1 HRP20190406TT HRP20190406T HRP20190406T1 HR P20190406 T1 HRP20190406 T1 HR P20190406T1 HR P20190406T T HRP20190406T T HR P20190406TT HR P20190406 T HRP20190406 T HR P20190406T HR P20190406 T1 HRP20190406 T1 HR P20190406T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
compound
disorder
Prior art date
Application number
HRP20190406TT
Other languages
English (en)
Croatian (hr)
Inventor
Florence Wagner Fevrier
Jennifer Q. Pan
Sivaraman Dandapani
Andrew Germain
Edward Holson
Benito Munoz
Partha P. Nag
Michel Weiwer
Michael C. Lewis
Stephen J. Haggarty
Joshua A. Bishop
Kimberly Stegmaier
Versha BANERJI
Original Assignee
The Broad Institute, Inc.
Dana-Farber Cancer Institute, Inc.
The General Hospital Corporation D/B/A Massachusetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation D/B/A Massachusetts General Hospital filed Critical The Broad Institute, Inc.
Publication of HRP20190406T1 publication Critical patent/HRP20190406T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HRP20190406TT 2012-10-12 2013-10-11 Inhibitori gsk3 i postupci njihove uporabe HRP20190406T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261713314P 2012-10-12 2012-10-12
US201361779394P 2013-03-13 2013-03-13
PCT/US2013/064716 WO2014059383A1 (en) 2012-10-12 2013-10-11 Gsk3 inhibitors and methods of use thereof
EP13780300.3A EP2909204B1 (en) 2012-10-12 2013-10-11 Gsk3 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20190406T1 true HRP20190406T1 (hr) 2019-05-31

Family

ID=49474737

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190406TT HRP20190406T1 (hr) 2012-10-12 2013-10-11 Inhibitori gsk3 i postupci njihove uporabe

Country Status (16)

Country Link
US (4) US9096594B2 (enExample)
EP (1) EP2909204B1 (enExample)
JP (2) JP6321662B2 (enExample)
CA (1) CA2887701C (enExample)
CY (1) CY1122601T1 (enExample)
DK (1) DK2909204T3 (enExample)
ES (1) ES2719776T3 (enExample)
HR (1) HRP20190406T1 (enExample)
HU (1) HUE043853T2 (enExample)
LT (1) LT2909204T (enExample)
PL (1) PL2909204T3 (enExample)
PT (1) PT2909204T (enExample)
RS (1) RS58700B1 (enExample)
SI (1) SI2909204T1 (enExample)
SM (1) SMT201900136T1 (enExample)
WO (1) WO2014059383A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
PL2970890T3 (pl) 2013-03-14 2020-11-16 The Brigham And Women's Hospital, Inc. Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016061344A1 (en) * 2014-10-15 2016-04-21 Mirx Pharmaceuticals Llc Gsk3 inhibitors and their uses
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CA3058198A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
CN110407769B (zh) * 2018-04-27 2022-11-08 复旦大学 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途
EP3801768A4 (en) 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2021102305A1 (en) * 2019-11-20 2021-05-27 Washington University Methods and compositions for generating functionally mature beta cells and uses thereof
WO2023056463A1 (en) * 2021-09-30 2023-04-06 Trustees Of Tufts College Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome
WO2024081939A2 (en) * 2022-10-13 2024-04-18 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
EP4727647A1 (en) 2023-06-14 2026-04-22 The Broad Institute Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
HUT74104A (en) 1993-04-08 1996-11-28 Du Pont Merck Pharma Novel polycyclic derivatives and pharmaceutical compositions containing them
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
CA2437215A1 (en) * 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
DK1746097T3 (da) * 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
WO2010098888A1 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
RS58700B1 (sr) * 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2014139870A (ja) * 2013-01-21 2014-07-31 Hitachi Consumer Electronics Co Ltd 照明装置およびこれを用いた映像表示装置
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
US10437707B2 (en) * 2015-03-19 2019-10-08 Teachers Insurance And Annuity Association Of America Evaluating and presenting software testing project status indicators
CA3058198A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Also Published As

Publication number Publication date
CY1122601T1 (el) 2021-03-12
JP2015536307A (ja) 2015-12-21
CA2887701C (en) 2020-12-15
JP2018150302A (ja) 2018-09-27
EP2909204B1 (en) 2018-12-05
SMT201900136T1 (it) 2019-05-10
PT2909204T (pt) 2019-03-21
US20220160702A1 (en) 2022-05-26
US20140107141A1 (en) 2014-04-17
DK2909204T3 (en) 2019-04-01
US20150313890A1 (en) 2015-11-05
SI2909204T1 (sl) 2019-06-28
EP2909204A1 (en) 2015-08-26
US11052080B2 (en) 2021-07-06
US10137122B2 (en) 2018-11-27
HUE043853T2 (hu) 2019-09-30
CA2887701A1 (en) 2014-04-17
US9096594B2 (en) 2015-08-04
JP6321662B2 (ja) 2018-05-09
PL2909204T3 (pl) 2019-07-31
JP6606691B2 (ja) 2019-11-20
LT2909204T (lt) 2019-05-10
US20200061050A9 (en) 2020-02-27
WO2014059383A1 (en) 2014-04-17
ES2719776T3 (es) 2019-07-16
RS58700B1 (sr) 2019-06-28
US20190175584A1 (en) 2019-06-13
US12419885B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
HRP20190406T1 (hr) Inhibitori gsk3 i postupci njihove uporabe
JP2015536307A5 (enExample)
ZA201806675B (en) Process for the preparation of enantiomerically enriched isoxazoline compounds ¿ crystalline toluene solvate of (s)¿afoxolaner
EP3576216A4 (en) PRECIOUS MATERIAL RECOVERY PROCESS FROM A USED LITHIUM-ION BATTERY
EP3434645A4 (en) METHOD FOR CONTINUOUS PRODUCTION OF GRAPHIC OXIDE NANOPLATES
EP2725905A4 (en) METHOD OF PREPARING CHIRAL DIPEPTIDYLPEPTIDASE IV INHIBITORS
IN2015DN04090A (enExample)
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
AR090291A1 (es) Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizan
MX2016002798A (es) Metodo para reutilizacion de cromatografia.
BR112015020883A2 (pt) processo e aparelho para purificação de uma corrente contendo um éster cíclico de um ácido alfa-hidroxicarboxílico
FR3025515B1 (fr) Procede de purification d'un anticorps monoclonal
FR3007404B1 (fr) Procede de preparation d'un film amorphe a base de sulfure ou d'oxysulfure metallique lithie
EP3516713A4 (en) METHOD FOR PRODUCING ELECTRODE ARRANGEMENTS
EP3527296A4 (en) RECYCLING PROCEDURE FOR USED VOIDABLE ARTICLES
EP3438048A4 (en) METHOD FOR PRODUCING BINAR-FREE, COAL-BASED, BRIKETTED ACTIVE CARBON
EP2969940A4 (en) PROCESS FOR PREPARING PURE CARBON AND METHOD THEREFOR
EP2927250A4 (en) (Fumaric acid diester) - (Cinnamic acid ester) copolymer, process for the preparation thereof and thus produced film
NZ724923A (en) Crystalline forms of grapiprant
EP3891114A4 (en) METHODS FOR THE PRODUCTION OF HIGH PURITY TRIFLUOROIODOMETHANE
ES2641372T3 (es) Inhibidores de replicación viral, su proceso de preparación y sus usos terapéuticos
EP2945946A4 (en) PROCESS FOR PREPARING AND CLEANING APIXABAN
TW201612240A (en) Composition for producing a sacrifice layer and process for producing the composition, and a semiconductor device having air gap produced using the composition and a process for producing a semiconductor device using the composition
EP3464229A4 (en) CONTINUOUS PROCESS FOR THE PRODUCTION OF MUCONIC ACID FROM ALDARIC ACID
EP3466913C0 (en) PROCESS FOR OBTAINING 1-OCTANOL